Genetics Program, Michigan State University, East Lansing, Michigan, USA.
J Virol. 2014 Jun;88(11):6232-42. doi: 10.1128/JVI.03869-13. Epub 2014 Mar 19.
Marek's disease (MD) is a lymphoproliferative disease of chickens caused by the oncogenic Gallid herpesvirus 2, commonly known as Marek's disease virus (MDV). MD vaccines, the primary control method, are often generated by repeated in vitro serial passage of this highly cell-associated virus to attenuate virulent MDV strains. To understand the genetic basis of attenuation, we used experimental evolution by serially passing three virulent MDV replicates generated from an infectious bacterial artificial chromosome (BAC) clone. All replicates became completely or highly attenuated, indicating that de novo mutation, and not selection among quasispecies existing in a strain, is the primary driving force for the reduction in virulence. Sequence analysis of the attenuated replicates revealed 41 to 95 single-nucleotide variants (SNVs) at 2% or higher frequency in each population and several candidate genes containing high-frequency, nonsynonymous mutations. Five candidate mutations were incorporated into recombinant viruses to determine their in vivo effect. SNVs within UL42 (DNA polymerase auxiliary subunit) and UL46 (tegument) had no measurable influence, while two independent mutations in LORF2 (a gene of unknown function) improved survival time of birds but did not alter disease incidence. A fifth SNV located within UL5 (helicase-primase subunit) greatly reduced in vivo viral replication, increased survival time of birds, and resulted in only 0 to 11% disease incidence. This study shows that multiple genes, often within pathways involving DNA replication and transcriptional regulation, are involved in de novo attenuation of MDV and provides targets for the rational design of future MD vaccines.
Marek's disease virus (MDV) is a very important pathogen in chickens that costs the worldwide poultry industry $1 billion to $2 billion annually. Marek's disease (MD) vaccines, the primary control method, are often produced by passing virulent strains in cell culture until attenuated. To understand this process, we identified all the changes in the viral genome that occurred during repeated cell passage. We find that a single mutation in the UL5 gene, which encodes a viral protein necessary for DNA replication, reduces disease incidence by 90% or more. In addition, other candidate genes were identified. This information should lead to the development of more effective and rationally designed MD vaccines leading to improved animal health and welfare and lower costs to consumers.
马立克氏病 (MD) 是一种由致瘤性禽疱疹病毒 2(通常称为马立克氏病病毒 (MDV))引起的鸡淋巴组织增生性疾病。MD 疫苗是主要的控制方法,通常通过在体外反复传代这种高度细胞相关病毒来产生,以减毒强毒 MDV 株。为了了解减毒的遗传基础,我们通过连续传代三个源自传染性细菌人工染色体 (BAC) 克隆的强毒 MDV 复制物来进行实验进化。所有复制物均完全或高度减毒,表明新突变,而不是现有株系中的准种选择,是降低毒力的主要驱动力。对减毒复制物的序列分析显示,在每个群体中,2%或更高频率的 UL42(DNA 聚合酶辅助亚基)和 UL46(被膜)中有 41 至 95 个单核苷酸变异(SNV),并且几个包含高频非同义突变的候选基因。将五个候选突变体整合到重组病毒中以确定其体内效应。UL42(DNA 聚合酶辅助亚基)和 UL46(被膜)内的 SNV 没有可测量的影响,而 LORF2(一个未知功能的基因)中的两个独立突变可提高鸟类的存活时间,但不改变疾病发生率。位于 UL5(解旋酶-引物酶亚基)内的第五个 SNV 大大降低了体内病毒复制,增加了鸟类的存活时间,导致疾病发生率仅为 0%至 11%。这项研究表明,多个基因,通常涉及 DNA 复制和转录调控途径,参与了 MDV 的从头衰减,并为未来 MD 疫苗的合理设计提供了目标。
马立克氏病病毒 (MDV) 是一种对鸡非常重要的病原体,每年给全球家禽业造成 10 亿至 20 亿美元的损失。马立克氏病 (MD) 疫苗是主要的控制方法,通常通过在细胞培养中传代强毒株,直到减毒。为了了解这个过程,我们鉴定了在反复细胞传代过程中病毒基因组中发生的所有变化。我们发现,UL5 基因中的一个单一突变,该基因编码病毒复制所必需的一种病毒蛋白,可将疾病发生率降低 90%或更多。此外,还确定了其他候选基因。这些信息应该会导致更有效和更合理设计的 MD 疫苗的开发,从而改善动物健康和福利,并降低消费者的成本。